Punctal Plug Can’t Keep QLT Afloat
Executive Summary
Five years ago, QLT Inc. charged in hard and snapped up an experimental drug-eluting punctal plug technology created by incubator ForSight Labs LLC. At the time, we reported in START-UP that the punctal plug – designed to deliver drugs directly into the eye – might make or break the company. Looks like it was the latter. Last month, QLT’s newly elected board of directors instituted a broad reshuffling of the company. The board cut the work force by 68% and it intends to divest the still-experimental punctal plug technology, hoping to sell the line outright or spin it out into another entity.
You may also be interested in...
QLT Shows Off Its Assets In Hopes Of Attracting A Suitor
The Canadian biotech has put itself on the block after a year of changes that have transformed the company from a commercial-stage entity with pipeline assets to a one-drug tax play.
Happy Return: QLT Bets Big on ForSight Plug
Publicly traded QLT Inc. is trying to capture lightning in a bottle; it has acquired the second company spawned by ForSight Labs, the incubator created by The Foundry. The still unnamed company has developed drug-eluting punctual plugs that QLT believes could challenge the $6 billion eye-drop industry.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.